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OBJECTIVE—We have previously shown that overexpression
of the Na-Ca exchanger (NCX1), a protein responsible for Ca2+
extrusion from cells, increases b-cell programmed cell death (ap-
optosis) and reduces b-cell proliferation. To further characterize
the role of NCX1 in b-cells under in vivo conditions, we devel-
oped and characterized mice deficient for NCX1.
RESEARCH DESIGN AND METHODS—Biologic and morpho-
logic methods (Ca2+ imaging, Ca2+ uptake, glucose metabolism,
insulin release, and point counting morphometry) were used to
assess b-cell function in vitro. Blood glucose and insulin levels
were measured to assess glucose metabolism and insulin sensi-
tivity in vivo. Islets were transplanted under the kidney capsule to
assess their performance to revert diabetes in alloxan-diabetic
mice.
RESULTS—Heterozygous inactivation of Ncx1 in mice induced
an increase in glucose-induced insulin release, with a major en-
hancement of its first and second phase. This was paralleled by
an increase in b-cell proliferation and mass. The mutation also
increased b-cell insulin content, proinsulin immunostaining, glu-
cose-induced Ca2+ uptake, and b-cell resistance to hypoxia. In
addition, Ncx1+/2 islets showed a two- to four-times higher rate
of diabetes cure than Ncx1+/+ islets when transplanted into di-
abetic animals.
CONCLUSIONS—Downregulation of the Na/Ca exchanger
leads to an increase in b-cell function, proliferation, mass,
and resistance to physiologic stress, namely to various changes
in b-cell function that are opposite to the major abnormalities
seen in type 2 diabetes. This provides a unique model for the
prevention and treatment of b-cell dysfunction in type 2 diabe-
tes and after islet transplantation. Diabetes 60:2076–2085,
2011
T
he prevalence of type 2 diabetes is progressing in
an alarming way in most regions of the world
(1,2). Type 2 diabetes is a complex disease
characterized by insulin resistance and b-cell
dysfunction. One of the earliest abnormalities occurring in
this disease is the alteration in pulsatile insulin release
with the suppression of the first phase of insulin response
to glucose (3). The second phase of insulin release is also
diminished and a number of abnormalities of continuous
insulin release have been observed (4,5). In addition to
a defect in b-cell function, a reduction in islet and b-cell
mass has been observed (6,7). This reduction could be
related to increased programmed cell death (apoptosis), to
decreased b-cell replication, or both (8).
In a previous work, we observed that overexpression of
the Na/Ca exchanger (isoform 1: Na-Ca exchanger [NCX1]),
a protein responsible for Ca2+ extrusion from cells (9,10),
increased b-cell apoptosis and reduced b-cell proliferation
(11). The increase in apoptosis resulted from endoplasmic
reticulum (ER) Ca2+ depletion with resulting ER stress
(11).
If it is possible to increase apoptosis and to decrease
b-cell proliferation by increasing the activity of NCX1,
it may be possible to obtain the opposite effects by
downregulating such a mechanism. To test this hypoth-
esis, we generated Ncx1 heterozygous deficient mice
(Ncx1+/2). Our data show that Ncx1+/2 heterozygous
inactivation induces several b-cell modifications, in-
cluding an increase in glucose-induced insulin release
and in b-cell proliferation and mass. Ncx1+/2 islets
also displayed an increased resistance to hypoxia, and
when transplanted in diabetic animals, showed a two- to
four-times higher rate of diabetes cure than Ncx1+/+
islets.
RESEARCH DESIGN AND METHODS
Generation of Ncx12/2 mice. Exon 11 of the murine Ncx1 gene (GenBank,
accession number AF409089) was cloned from a 129/Sv genomic phage li-
brary. The first 206-bp were amplified by PCR and a BamHI site was in-
troduced for cloning. A targeting vector was constructed by inserting the
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neomycin resistance cassette (neo) into the BamHI restriction site of that
amplified exon. Standard procedures were used to generate Ncx1+/2 mice
(12). Except as otherwise stated, experimental mice were 2 to 6 months old, of
both sexes, and had F2 genetic backgrounds from 129/Sv and CD1 mice.
Ncx1+/+ mice consisted of age-matched littermates with two wild-type (WT)
alleles at the Ncx1 locus (Ncx1+/+).
Intracellular Ca
2+
concentration measurements. The measurement of
intracellular Ca2+ concentration using fura-2 was done, as previously de-
scribed (11,13), using a camera-based image analysis system (MetaFluor,
Universal Imaging, Ypsilanti, MI).
Time-frequency analysis of spectral densities of the Ca2+ oscillations was
computed using Ackqnowledge Software, (Biopac Systems, Goleta, CA), with
a Hamming window. Data were segmented in successive epochs of 1 min. We
computed the power spectral density (PSD), the integral below the power
spectrum for the frequency band 0–0.17 Hz, and the crest factor for the same
frequency band (ratio amplitude of the power spectra/integral 0–0.17 Hz).
45
Ca uptake, insulin content, and insulin release from isolated islets.
The methods used to measure 45Ca uptake in intact islets and insulin release
from perifused islets are described in detail elsewhere (11,13–15). Insulin was
assayed using an ELISA kit (Mercodia, Uppsala, Sweden). For the measure-
ment of insulin content, the islets were homogenized in water in the absence
of glucose.
Measurement of glucose metabolism and morphology. The methods used
to measure D-[5-3H]glucose metabolism and D-[U-14C]glucose oxidation in in-
tact islets, have been previously described (16,17).
Golgi proinsulin/b-cell area was evaluated on slides stained for proinsulin
with immunoperoxidase (18) digitized through a JVC KY-F58 color digital
camera (Japan Victor, Brussels, Belgium). Tissues sections (5-mm thick) were
prepared according to Jacoby et al. (19) and processed for hematoxylin-eosin
staining.
For electron microscopy, groups of 30 islets were fixed, epoxide-embedded,
and analyzed as described previously (20).
Measurement of b-cell proliferation, apoptosis, mass, and size. To
measure b-cell proliferation, mice were injected intraperitoneally with
5-bromo-2-deoxyuridine (BrdU, Sigma-Aldrich, St. Louis, MO; 100 mg/kg body
wt) 6 h before euthanasia, as previously described (21). An alternative method
to measure b-cell replication was the Ki67 labeling method (rabbit monoclonal
anti-Ki67, Vector Laboratories, Brussels, Belgium) with a method similar to the
BrdU immunofluorescence labeling (22).
To measure b-cell apoptosis, the terminal deoxynucleotidyltransferase
mediated dUTP nick-end labeling (TUNEL) method was used, with the In Situ
Cell Death Detection Kit (Roche Diagnostics, Vilvoorde, Belgium). The
method for b-cell labeling and counting was similar to that for b-cell pro-
liferation.
Cell viability in vitro was measured using Hoechst 33342 (Ho342) and
propidium iodide (PI) (23). The percent viability in Ncx1+/+ single b-cells
and islets (not exposed to thapsigargin or cyclopiazonic acid) was 65% to
70% and 85% to 95%, respectively. In some experiments, cytokines were
used at the following concentrations: human IL-1b: 50 units/mL (R&D Sys-
tems, Oxon, UK); mouse interferon-g: 1000 units/mL (tebu-bio, Boechout,
Belgium).
Quantification of b-cell mass was performed by point-counting morphom-
etry of insulin-peroxidase immunostained pancreatic sections, as previously
described (24). Individual b-cell size was measured using the calibrated
ImageJ (National Institutes of Health, Bethesda, MD) image analysis program.
The b-cell area of the pancreatic section was divided by the number of b-cell
nuclei identified in the area.
In vitro hypoxia studies. In vitro hypoxia studies were as previously de-
scribed (25). The duration of hypoxia was 6 h. Viability of b cells was mea-
sured as described above.
Glucose metabolism, insulin sensitivity, serum glucagon, growth hormone,
and glucagon-like peptide 1 measurement in vivo. The measurement of
glucose metabolism and insulin sensitivity in vivo were done as previously
described (26,27). Serum glucagon, growth hormone, and glucagon-like
peptide 1 (GLP-1) were measured using Glucagon Human/Mouse/Rat ELISA
(Alpco, Salem, NH), Rat/Mouse Growth Hormone ELISA Kit (Millipore,
St. Charles, MO), and Mouse GLP-1 ELISA kit (Antibodies-online.com, Aachen,
Germany).
Diabetes induction and islets transplantation. Diabetes was induced in 10-
to 12-week-old C57BL6N mice using a single intravenous injection of alloxan
(90 mg/kg; Sigma) (25,26). Grafts of 50 to 400 islets from Ncx1+/+ or Ncx1+/2
mice were transplanted under the kidney capsule in diabetic mice. Thereafter,
the nonfasting blood glucose levels were measured in each animal up to 100
days, using a Glucometer (Abbott, Diegem, Belgium). Islet grafts were con-
sidered functional when the nonfasting blood glucose returned to normogly-
cemic levels (,220 mg/dL). In some animals, the graft-bearing kidney was
removed to confirm islet graft function.
Statistics. The results are expressed as means 6 SEM. The statistical sig-
nificance of differences between data was assessed by using ANOVA, followed
by the Tukey post-test.
RESULTS
Generation of Ncx12/2 mice. A mutant allele was con-
structed as described in RESEARCH DESIGN AND METHODS (Fig.
1A). After electroporation with the targeting vector, the
recombinant embryonic stem cell clones were identified
by DNA hybridization and used to produce chimeric mice
(Fig. 1B). Transmission of the mutant allele produced
Ncx1 heterozygous mice that were mated to generate Ncx1
null mutants (Ncx12/2). The Ncx12/2 mice were not viable
and died during embryogenesis as described (28). Het-
erozygous and WT mice genotyping from tail biopsy
specimen DNA revealed an Ncx1 WT amplicon of ;250 bp
and an Ncx1 recombinant allele of ;100 bp, which were
simultaneously amplified by PCR (Fig. 1C). NCX1 mRNA
levels in batches of islets from Ncx1+/+ and Ncx1+/2 mice,
measured using RT-PCR, showed a clear decrease inNcx1+/2
mice (Fig. 1D). Ncx1+/2 mice were viable, fertile, had
a normal body weight, and showed no macro- or micro-
scopic abnormalities at the level of the brain, heart, lung,
liver, spleen, stomach, intestine, and thymus (Supplemen-
tary Fig. 1). Likewise, serum levels of glucagon, growth
hormone (GH) in the fasting state and GLP-1 in the fed
state were comparable in Ncx1+/+ and Ncx1+/2 mice at 12
weeks (0.48 6 0.04 vs. 0.41 6 0.14 ng/mL, 2.4 6 0.44 vs.
1.67 6 0.44 ng/mL, and 3.20 6 0.28 vs. 2.86 6 0.15 pg/ml,
respectively; n = 4 in each case, except for GH where n =
9–11, respectively, P . 0.05).
Na/Ca exchange activity in Ncx1+/2 islets. To evaluate
the functional consequences of Ncx1 heterozygous in-
activation, the activity of the Na/Ca exchanger was eval-
uated by measuring the effect of extracellular Na+ removal
on 45Ca uptake and cytosolic free Ca2+ concentration ([Ca2+]i),
and of K+-induced membrane depolarization on [Ca2+]i.
Removal of extracellular Na+ increased 45Ca uptake in
Ncx1+/+ and Ncx1+/2 islets (Fig. 1E), the uptake in Ncx1+/2
islets recorded in the absence of extracellular Na+ being
half of that measured in Ncx1+/+ islets. Removal of extra-
cellular Na+ induced a sustained increase in [Ca2+]i (Fig. 1F),
that again was reduced in Ncx1+/2 compared with Ncx1+/+
islets. Thus, the increase in [Ca2+]i induced by the absence
of extracellular Na+, measured as the area under the curve
over the baseline value during a 5- to 25-min period was
reduced by 24% in Ncx1+/2 compared with Ncx1+/+ islets
(P , 0.05). K+ increased [Ca2+]i in both types of islets
(Fig. 1G), but [Ca2+]i was always slightly higher in Ncx1
+/2
than in Ncx1+/+ mice. The difference in mean concentration
was higher (36%) during the period of K+ exposure (min 2–
12) and of K+ removal (65%; min 12–24) than during the
baseline period (min 0–2; P , 0.001), indicating that Ca2+
extrusion was mainly impaired during the period of K+
stimulation and recovery. Taken as a whole, these data in-
dicate that partial Ncx1 heterozygous inactivation reduces
Na/Ca exchange activity in islet cells both in its forward and
reverse mode. We then examined the effect of Ncx1 het-
erozygous inactivation on islet function.
Islet function in Ncx1+/2 islets
Insulin release. Figure 2A and B shows the effect of
an increase in glucose concentration from 2.8 to 11.1
mmol/L on insulin release from perifused islets (A: rep-
resentative experiment, B: mean of 4–6 experiments). In
Ncx1+/+ islets, glucose induced an oscillatory increase
E. NGUIDJOE AND ASSOCIATES
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in insulin release. In Ncx1+/2 islets, glucose induced a
marked first-phase insulin release, followed by a pro-
gressive increase with less clear oscillations. The amount
of insulin released during the entire period of stimulation
(16–60 min) was about 2.4-times higher in Ncx1+/2 than in
Ncx1+/+ islets (P , 0.02). A similar observation was made
at 16.7 mmol/L glucose, where the fold-increase was 1.7
(P , 0.05), or by perifusing a single islet, where the fold-
increase in response to 11.1 mmol/L glucose was 2.6 (P ,
0.05, Supplementary Figs. 2 and 3, respectively).
Glucose-induced increase in [Ca2+]i. Oscillatory insulin
release is associated with oscillatory [Ca2+]i increases
(29,30). Figure 2C and D shows the effect of 11.1 mmol/L
glucose on [Ca2+]i oscillations in intact islets. Ncx1
+/+ islets
showed a rapid increase in [Ca2+]i with an initial phase,
followed by a second phase displaying regular oscillations.
Ncx1+/2 islets also showed a rapid increase in [Ca2+]i
but the initial phase was more distinct, separated from the
second phase, which displayed disrupted [Ca2+]i oscillations.
Figure 2E and F shows at a larger scale the oscillations
FIG. 1. Targeted disruption of the Ncx1 gene and Na/Ca exchange activity in Ncx1+/+ and Ncx1+/2 islets. A: Structure of the WT and the targeted
alleles. The eleventh exon, the neomycin resistance cassette, and the probes used in DNA and RNA hybridization analysis (bars underneath the
targeted allele) are represented. B: DNA hybridization analysis of BamHI digested genomic DNA isolated from embryonic stem cell clones using
the depicted probe. RH, recombinant homolog. C: PCR analysis for genotyping. D: Ncx1 mRNA levels in batches of islets from Ncx1+/+ and Ncx1+/2
mice. GAPDH, glyceraldehyde-3-phosphate dehydrogenase. E: 45Ca uptake in the presence and the absence of extracellular Na+. Means 6 SEM of







and Ncx1+/2 islets. The period of exposure to Na+-free medium is indicated by a bar above the curves.
The curves shown are the mean of seven traces in each case. G: Effect of KCl (50 mmol/L) on [Ca2+]i in Ncx1
+/+
and Ncx1+/2 islets. The period of
exposure to KCl is indicated by a bar above the curves. The curves shown are the mean of 13 traces in each case.
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during the period 14–16 min. The number of oscillations is
easily determined and counted in Ncx1+/+ islets, at variance
with Ncx1+/2 islets, where the oscillations are irregular and
difficult to identify. PSD analysis of the oscillations showed
that Ncx1+/+ islets displayed a single peak with a very stable
generator in frequency and magnitude (Fig. 2G), whereas
Ncx1+/2 islets displayed an unstable dominant frequency and
numerous peak intrusions above the frequency of 0.10 Hz,
FIG. 2. Effect of Ncx1 heterozygous inactivation on glucose-induced insulin release and [Ca2+]i oscillations. Effect of 11.1 mmol/L glucose on
insulin release (A and B) and [Ca2+]i (C and D) from groups of 20 islets: representative experiment (A), mean of four (Ncx1
+/+
) and six (Ncx1+/2)
individual experiments (B). C and D show typical individual traces observed in Ncx1+/+ and Ncx1+/2 islets, respectively. The curves are repre-
sentative of seven and eight individual traces, respectively. The period of exposure to glucose 11.1 mmol/L is indicated by a bar above the curves. In
both cases, the islets were from different mice. E and F present the same traces as in panels C and D, showing the [Ca2+]i oscillations between min
14 and 16 on a larger scale. G and H: Power spectral analysis of the oscillations observed in typical individual traces. (A high-quality digital
representation of this figure is available in the online issue.)
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illustrating the irregularity of the oscillations (Fig. 2H).
Supplementary Fig. 4A and B also shows that there was
a significant difference both in the magnitude of the peak
of power spectra (Max PSD) and in the crest factor (ratio
Max/Integral) between Ncx1+/+ and Ncx1+/2 islets.
Glucose metabolism. To stimulate insulin release, glu-
cose must be metabolized by the pancreatic b-cell (31). In
Ncx1+/+ and Ncx1+/2 islets, the utilization of D-[5-3H] glucose
increased as a result of the rise in the glucose concentration
from 2.8 to 16.7 mmol/L (Fig. 3A). At the low hexose
concentration, 3H2O generation from D-[5-
3H]glucose was
slightly higher in Ncx1+/2 than in Ncx1+/+ cells.
Generation of 14CO2 from D-[U-
14C]glucose was also in-
creased in response to the rise in glucose concentration in
both type of islets (Fig. 3B). However, although oxidation
tended to be higher in Ncx1+/2 islets at the low glucose
concentration, glucose oxidation was significantly lower in
Ncx1+/2 than in Ncx1+/+ cells at the high glucose concen-
tration. As a result of these differences, the paired ratio
between D-[U-14C]glucose oxidation and D-[5-3H]glucose
utilization increased with the rise in glucose concentration
in Ncx1+/+ cells (P , 0.05), but it did not change in Ncx1+/2
cells. Compared with Ncx1+/+ cells, ATP generation tended
to be increased in Ncx1+/2 islets at low (53%) but reduced at
high glucose concentration (220%, P , 0.05, Supplemen-
tary Table 1).
Uptake of 45Ca in response to glucose. Glucose-
induced insulin release is preceded by Ca2+ uptake in the
b-cell (32). In Ncx1+/+ and Ncx1+/2 islets, 16.7 mmol/L
glucose stimulated 45Ca uptake (Fig. 3C). Whereas at low
glucose, there was no significant difference in 45Ca uptake
between the two types of islet; the increase in uptake
induced by 16.7 mmol/L glucose was twice as high in
Ncx1+/2 than in Ncx1+/+ islets.
Insulin content. In view of the major increase in insulin
release in Ncx1+/2 islets, the insulin content of the islets
was measured and was about double that of Ncx1+/+ islets
(Fig. 3D).
Morphology. There were no differences in islet morphol-
ogy or in the position of b-, a-, and d-cells between Ncx1+/+
and Ncx1+/2 islets (data not shown). Proinsulin staining,
however, was increased in Ncx1+/2 compared with Ncx1+/+
islets (Fig. 4A) of adult mice (12–14 weeks), a finding in line
with the increase in insulin content. Electron microscopic
analysis revealed no difference in the features of pancreatic
b-cells, including secretory granules, nucleus, mitochondria,
FIG. 3. Effect of Ncx1 heterozygous inactivation on glucose metabolism, 45Ca uptake, and insulin content. Metabolism of D-[5H]glucose (A) and
D-[U-
14
C]glucose (B) is shown in Ncx1+/+ and Ncx1+/2 islets. Mean 6 SEM values are shown for 12 to 25 individual determinations. A: ***P < 0.001
vs. 2.8 mmol/L. B: ***P < 0.01 vs. 2.8 mmol/L; #P < 0.01 vs. Ncx1+/+ islets at 16.7 mmol/L glucose. C: Effect of glucose on 45Ca uptake in Ncx1+/+ and
Ncx1+/2 islets. Mean 6 SEM values are shown for four experiments, comprising four to six replicates in each case. *P < 0.05; ***P < 0.001 vs. 2.8
mmol/L; #P < 0.01 vs. Ncx1+/+ islets at 16.7 mmol/L glucose. D: Insulin content of batches of 10 islets (means 6 SEM of 14 and 7 individual
determinations). **P < 0.01 vs. Ncx1+/+ islets.
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ER, and Golgi apparatus of Ncx1+/+ and Ncx1+/2 adult mice
(Fig. 4B). Quantitative analysis of relative volume of organ-
elles demonstrated no significant difference between Ncx1+/+
and Ncx1+/2 b-cells (data not shown).
Taken as a whole, the data so far presented show that
Ncx1 heterozygous inactivation strongly increases glucose-
induced insulin production and release.
b-Cell mass, size, proliferation, and viability. b-Cell
mass, size, and proliferation was measured in young
(4 weeks) and adult (12 weeks) mice (Fig. 5A–C). As
expected, b-cell mass was increased at 12 weeks in both
types of islet, although the increase was of much larger
magnitude in Ncx1+/2 than in Ncx1++ islets (8.8- vs. 1.6-fold
increase, respectively, P , 0.001; Fig. 4C). This increase
was not due to b-cell or islet hypertrophy because no
change in b-cell and islet size was observed between
Ncx1+/+ and Ncx1+/2 mice (Fig. 5B and data not shown);
rather, it was due to an increase in the b-cell proliferation
rate. As expected, b-cell proliferation, as measured using
BrdU, was decreased at 12 weeks compared with 4 weeks
(Fig. 5C), although the decrease was of a lower magnitude
in Ncx1+/2 than in Ncx1+/+ islets (240 vs. 285%, P , 0.01).
As a result, a 5.25-times higher proliferation rate was ob-
served at 12 weeks in Ncx1+/2 compared with Ncx1+/+
mice (Fig. 5C and Supplementary Fig. 5). We also observed
an increase in proliferation rate of the exocrine pancreatic
cells that was lower than in the endocrine pancreas (1.7-
vs. 5.25-fold increase, respectively; P , 0.02, Supplemen-
tary Fig. 5). Ki67 staining showed an increased labeling in
Ncx1+/2 compared with Ncx1+/+ islets, with the number
of positive nuclei averaging 2.75 6 0.31 vs. 1.58 6 0.28 per
islet, respectively (P , 0.01).
Apoptosis of b-cells was also measured, but no differ-
ence could be found between Ncx1+/2 and Ncx1+/+ islets.
Thus, whether using the TUNEL method at 4 and 12 weeks
under basal conditions (Fig. 5D), or Ho342 and PI staining
of islet cells (Fig. 5E–G) under basal or stimulated conditions
created by the absence or presence of sarcoendoplasmic
reticulum Ca2+ ATPase (SERCA) inhibitors (Fig. 5E), and
72-h exposure of intact islets to cytokines (Fig. 5F) or
thapsigargin (Fig. 5G), no difference could be found be-
tween both types of islets.
Hypoxia studies. To test their resistance to physiologic
stress, the islets were then subjected to hypoxia for 6 h,
cell death being measured using Ho342 and PI staining of
intact islets. Figure 5H shows that 71% of Ncx1+/+ islets
showed a decrease in viability,60% compared with 45% of
Ncx1+/2 islets.
Transplantation. We then transplanted Ncx1+/2 islets
under the kidney capsule of alloxan-diabetic mice to ex-
amine their performances compared with Ncx1+/+ islets.
First, we had to determine the minimum number of Ncx1+/+
islets to transplant to cure diabetes, which must be ;300
islets. Indeed, all transplantations with 400 islets were
successful, with nephrectomy leading to a reincrease in
glycemia (Supplementary Fig. 6A), whereas the rate of
success of transplantation of 200 Ncx1+/+ islets was only 2/5
(Supplementary Fig. 6B). In comparison, the rate of success
of transplantation of 100 Ncx1+/2 islets was 4/5 (Supple-
mentary Fig. 6C), whereas the rate of success of trans-
plantation of 50 Ncx1+/2 islets was 2/3 (Supplementary Fig.
5D). This suggests that the Ncx1+/2 islets are at least four-
to seven-times more efficient to cure diabetes than the
Ncx1+/+ islets. Finally, we performed a last series of parallel
transplantations of 100 islets (Fig. 6A and B). The success
rate was 4/5 and 2/5 for Ncx1+/2 and Ncx1+/+ islets, in-
dicating that the Ncx1+/2 islets are at least twice as efficient
in curing diabetes than Ncx1+/+ islets.
Morphometric analysis of the islet grafts after nephrec-
tomy of mice who received a transplant of 100 islets
showed that the relative volume of islet grafts was about
seven-times higher in cured than in noncured animals
(4.26 6 1.09% vs. 0.61 6 0.39%, respectively [n = 4–6]; P ,
0.05), confirming that diabetes cure is attributable to islet
transplantation.
Glucose metabolism and insulin sensitivity in vivo.
Despite the major increase in insulin release seen in vitro,
plasma glucose and insulin levels were comparable in
Ncx1+/2 and Ncx1+/+ mice, both in the fasted and the fed
state (Fig. 6C and E). However, the glucose-tolerance test
showed an increased and earlier initial peak of insulin
release (Fig. 6D and F), with a subsequent faster decrease
in glucose levels during the ensuing 45 min (2152 6 20
compared with 281 6 2 mg/dL in Ncx1+/2 and Ncx1++
mice, respectively, P , 0.01). The intraperitoneal insulin
sensitivity test showed no difference between the mice
(Supplementary Fig. 7).
FIG. 4. Effect of Ncx1 heterozygous inactivation on islet morphology. A:
Immunohistochemistry: proinsulin labeling (immunoperoxidase in
brown) is stronger in Ncx1+/2 than in Ncx1+/+ islets. Representative
images of six 12-week-old mice pancreas sections in each case. Inset:
Same image at higher magnification (original magnification 363). B:
Transmission electron microscopy. Groups of 30 islets from Ncx1+/+ and
Ncx1+/2 mice were fixed, and three sections in each block demon-
strating an islet were cut at randomly chosen depths. The characteristic
ultrastructural features of pancreatic b-cells were comparable in both
types of islets. Representative images are shown of b-cells from 12-
week-old mice Ncx1+/+ (left panel) and Ncx1+/2 islets (right panel).
Scale bar = 2 mm. C: Representative images of pancreatic b-cells
immunolabeled with immunoperoxidase (brown) using a polyclonal
anti-insulin antibody, with hematoxylin used for the counterstain. The
sections were used to evaluate the b-cell mass by counting morphom-
etry. The photomicrographs represent 12-week-old mice pancreatic
sections of Ncx1+/+ (left panel) and Ncx1+/2 islets (right panel). Scale
bar = 0.2 mm. (A high-quality digital representation of this figure is
available in the online issue.)
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FIG. 5. Effect of Ncx1 heterozygous inactivation is shown on b-cell mass (A), size (B), proliferation rate (C), and apoptosis (D) between weeks
4 and 12 in Ncx1+/+ and Ncx1+/2 mice. Mean 6 SEM values are shown from five and six pancreas specimens, respectively. A: ***P < 0.001 vs. values
at 4 weeks; #P < 0.001 vs. Ncx1+/+ b-cells at 12 weeks. C: **P < 0.01; ***P < 0.001 vs. respective value at 4 weeks; #P < 0.01 vs. Ncx1+/+ islets at
12 weeks. Cell viability was measured in isolated islet cells (E) and in intact islets (F, G, H) using Ho342 and PI staining in the absence or after
72-h exposure to thapsigargin (Thaps) or cyclopiazonic acid (CPA) (E and G), cytokines (Cyt; F), and after 6-h exposure to hypoxia (H). Mean 6
SEM values are shown from four individual experiments. F: *P < 0.05 vs. control in the absence of cytokines. G: **P < 0.01 vs. respective Ncx1
islets in the absence of Thaps. H: *P < 0.05 vs. Ncx1+/+ islets.
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ER Ca
2+
stores. In a previous study we showed that
NCX1 overexpression increased b-cell apoptosis and de-
creased b-cell proliferation by depleting ER Ca2+ stores
(11). Therefore, we wondered whether the opposite
changes seen in the current study in Ncx1+/2 mice were
not due to an increase in ER Ca2+ stores. To test this hy-
pothesis, the effect of the SERCA inhibitor thapsigargin on
[Ca2+]i in pancreatic islets was examined (Supplementary
Fig. 8). In Ncx1+/+ islets, thapsigargin induced an impor-
tant but transient increase in [Ca2+]i, a phenomenon that
was increased by about 60% in Ncx1+/2 islets (P , 0.05),
indicating that ER Ca2+ stores were increased in Ncx1+/2
compared with Ncx1+/+ islets.
DISCUSSION
We generated a mouse strain with heterozygous in-
activation of the gene coding for NCX1, the isoform of the
Na/Ca exchanger that is expressed in the pancreatic b-cell
(33). RT-PCR studies confirmed heterozygous inactivation
of the exchanger in Ncx1+/2 mice and the reduction of its
expression in b-cells. The latter reduction led to a de-
crease in NCX1 activity as assessed at the physiologic
FIG. 6. Effect ofNcx1 heterozygous inactivation on islets transplantation and glucose metabolism is shown in vivo. Effect of transplanting grafts of
100 islets from Ncx1+/+ (A) or Ncx1+/2 (B) mice is shown on nonfasting blood glucose levels. The success rate of diabetes cure (blood glucose level
<220 mg/dL) was 2/5 for Ncx1+/+ and 4/5 for Ncx1+/2 islets. Nephr, nephrectomy. C and E: Glycemia and insulin levels measured in the fasting and
the fed state of Ncx1+/+ and Ncx1+/2 mice (n = 5 in each case). D and F: Glycemia and insulin levels are shown during an intraperitoneal glucose
tolerance test in Ncx1+/+ and Ncx1+/2 mice (n = 8 in each case). *P < 0.05. Data are shown as the means 6 SEM.
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level, with inhibition of both modes of the exchanger
(forward and reverse). The reduction in Na/Ca exchange
activity in Ncx1+/2 b-cells had multiple consequences:
First, as expected from cells from which Ca2+ extrusion is
reduced, the rise in [Ca2+]i induced by membrane de-
polarization and the uptake of 45Ca induced by glucose
were increased.
Second, the [Ca2+]i oscillations induced by the sugar
were disrupted. This was not unexpected, because the
exchanger generates an inward current when working in
its forward mode that contributes to the duration of the
bursts of electrical activity (34) that underlie [Ca2+]i
oscillations (35,36). Hence, the reduction of the NCX1 in-
ward current in Ncx1+/2 cells led to the shortening and
disorganization of the oscillations. However, in view of the
decreased rate of ATP generation at high glucose in Ncx1+/2
compared with Ncx1+/+ islets, the disruption of the Ca2+
oscillations could also be due to an attenuation of the met-
abolic oscillations that underlie the slow electrical and Ca2+
oscillations via a relief of phosphofructokinase inhibition by
ATP (37).
Third, glucose-induced insulin release was markedly
increased. Both phases of insulin release were enhanced,
which could also be related to the reduction in Ca2+ ex-
trusion with subsequent increase in cellular Ca2+ content
as objectified at the ER level. In view of this major increase
in insulin release, we next examined insulin content, islet
morphology, and glucose metabolism.
Insulin content was doubled in Ncx1+/2 compared with
Ncx1+/+ b-cells, but no change in morphology was found
between the cell types except for an increase in pro-
insulin staining in Ncx1+/2 b-cells, a finding compatible
with the increase in insulin content. In Ncx1+/2 b-cells,
there was a tendency toward an increase in glucose uti-
lization at low glucose concentration and a significant
decrease in glucose oxidation at high glucose concen-
tration, making it unlikely that the observed increase
in glucose-induced insulin release in these islets is
explained by an augmented mitochondrial glucose me-
tabolism. The increase in the insulin secretory rate may
result instead from increased insulin production and
cellular Ca2+ content.
We next looked at b-cell mass, size, proliferation, and
death. At 12 weeks (adult mice), b-cell mass had increased
100% in Ncx1+/2 compared with Ncx1+/+ mice, a phenom-
enon that was not due to an increase in b-cell size but
rather to an increase in b-cell proliferation, the rate of
which was five-times higher in Ncx1+/2 mice than in
Ncx1+/+ mice. The view that a decrease in b-cell death
could also contribute to this observation was examined,
but the results obtained were negative except in the case
of hypoxia. Indeed, although measurement by the TUNEL
method showed no difference in the rate of apoptosis
under basal conditions and no difference in viability be-
tween single cells or islets of Ncx1+/+ and Ncx1+/2 mice
under basal and stimulated conditions, Ncx1+/2 islets
showed a 37% protection against hypoxia compared with
Ncx1+/+ islets.
The increase in b-cell function, growth, and resistance to
the physiologic stress of Ncx1+/2 islets was confirmed in
transplantation studies, the Ncx1+/2 islets being at least
twice as efficient in curing diabetes than the Ncx1+/+ islets.
In this respect, it is important to know that islets trans-
plantation represents a valuable approach in the treatment
of diabetes. However, its applicability is limited by the
need to transplant a high number of islets from two or
more donors. In clinical islet transplantation, it has been
estimated that up to 70% of the transplanted b-cell mass is
destroyed in the early post-transplant period due to non–
immune-mediated physiologic stress, namely prolonged
hypoxia during the revascularization process (38).
The increase in insulin content, b-cell proliferation, and
mass seen in Ncx1+/2 islets could result from the activa-
tion by raised cellular Ca2+ of the calcineurin/nuclear
factor of activated T-cell (NFAT) signaling pathway.
Calcineurin is a calmodulin-dependent serine/threonine
phosphatase that dephosphorylates the cytoplasmic sub-
units of NFAT (NFATc) upon activation by Ca2+. De-
phosphorylation of NFATc allows its rapid translocation to
the nucleus, with subsequent activation of insulin tran-
scription and promotion of b-cell proliferation by in-
creasing the expression of cell cycle promoters such as
cyclin D1, cyclin D2, and cyclin-dependent kinase 4 (CDK4)
(39). b-Cell–specific calcineurin inactivation in knockout
mice impaired insulin transcription and cyclins expression,
leading to markedly decreased b-cell proliferation and mass
and to diabetes onset (40). Interestingly, calcineurin in-
activation did not increase b-cell apoptosis (39), a finding
compatible with the absence of a decrease in b-cell apo-
ptosis observed in this study.
Last, except for a higher initial peak of insulin release
during the glucose tolerance test, no difference was found
in in vivo glucose metabolism or in insulin resistance be-
tween both mice.
In conclusion, heterozygous inactivation of a single gene
(Ncx1) leads to an increase in insulin release, b-cell pro-
liferation and mass, and to an increase in resistance to b-cell
death, namely, to various changes in b-cell function that are
opposite to the major abnormalities seen in type 2 diabetes.
Moreover, it increased the success rate of islet trans-
plantation in diabetic animals. Downregulation of the b-cell
Na/Ca exchanger is thus a unique model providing a novel
concept for the prevention and treatment of type 2 diabetes
and to improve the applicability of islet transplantation.
ADDENDUM
During the process of submitting the present work for
publication, another study showed that KB-R7943, an
NCX1 inhibitor, enhanced glucose-induced insulin release,
a finding confirming part of our results (41).
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